H.C. Wainwright Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $80
Promising Potential of Structure Therapeutics' ACCG-2671 Drives Buy Rating
Buy Rating for Structure Therapeutics, Inc. Driven by Innovative Drug Development and Promising Obesity Treatment Platform
Express News | Shares of Viking Therapeutics up 4.2%, Amgen up 1%
Express News | Weight Loss Drug Developers Rise Intraday Trading After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected
Structure Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
